A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol

Inclusion Criteria

• Provision of signed and dated, written informed consent prior to any study specific procedures.
• Healthy male and female subjects aged 18 to 50 years (inclusive) with suitable veins for cannulation or repeated venepuncture.
• Have a body mass index between 18 and 30 kg/m^2 (inclusive) and weigh at least 50 kg and no more than 100 kg (inclusive).
• Females must have a negative pregnancy test at screening and on admission to the unit and must be:
• not pregnant or currently lactating or breastfeeding.
• of non-childbearing potential, confirmed at screening by fulfilling one of the following criteria: (i) postmenopausal defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle stimulating hormone (FSH) levels in the postmenopausal range (FSH levels > 40 IU/mL).

(ii) documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.

• OR if of childbearing potential must be willing to use an acceptable method of contraception to avoid pregnancy for the entire study period.
• Must be able to swallow multiple capsules and tablets.

Exclusion Criteria

• History of gout or any clinically significant disease which, in the opinion of the principal investigator (PI), may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study.
• Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of verinurad.
• History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• Any clinically important abnormalities in clinical chemistry, haematology or urinalysis results as judged by the Investigator at screening and first admission, including:
• Alanine aminotransferase > 1.5 x upper limit of normal (ULN),
• Aspartate aminotransferase > 1.5 x ULN,
• Bilirubin (total) > 1.5 x ULN,
• Gamma glutamyl transpeptidase > 1.5 x ULN.
• Any clinically significant abnormal findings in vital signs at the Screening Visit and/or admission to the Clinical Unit, including, but not limited to, any of the following:
• Pulse (resting, supine) 90 bpm,
• Systolic blood pressure (BP) 140 mmHg and/or diastolic BP 90 mmHg sustained for > 10 minutes while resting in a supine position.
• Any clinically significant abnormalities on 12 lead electrocardiogram (ECG) at the Screening Visit, including, but not limited to any of the following:
• QTcF > 450 ms or 240 ms); intermittent second or third degree AV block, or AV dissociation
• Complete bundle branch block and/or QRS duration > 120 ms.
• Any positive result at the Screening Visit for serum Hepatitis B surface antigen or Anti Hepatitis B core antibody, hepatitis virus C antibody, and human immunodeficiency virus antibody.
• Suspicion or known Gilbert's and/or Lesch Nyhan syndrome.
• Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as judged by the PI.
• Has received another new chemical or biological entity within 30 days or at least 5 half lives of the first administration of verinurad in this study.
• Subjects who have previously received verinurad.
• Plasma donation within 1 month of screening or any blood donation/loss of more than 500 mL during the 3 months prior to the Screening Visit.
• Subjects who are pregnant, lactating or planning to become pregnant.
• Hypersensitivity to verinurad, allopurinol or any drug with a similar chemical structure/class to verinurad and/or allopurinol.
• Current smokers or those who have smoked or used nicotine products (including e cigarettes) within the 3 months prior to screening.
• Excessive intake of caffeine containing drinks or food as judged by the PI.
• Positive screen for drugs of abuse or cotinine (nicot